# Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

Source: https://onco.cc/trials/nct06547203/  
OnCo record `nct06547203` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cetuximab, toripalimab and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study is a phase 2, interventional study registered as NCT06547203 by Sun Yat-sen University, with a registry enrolment figure of 34 participants, started 2024-07-18 and due to reach its primary completion in 2026-07-30. Interventions recorded: Cetuximab; Toripalimab; Irinotecan. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06547203
- Phase: 2
- Setting: Negative Ultraselection of Patients With RAS/BRAF Wild-type Refractory Right-Sided Metastatic Colorectal Cancer Receiving Cetuximab in Combination With Toripalimab and Irinotecan: A Phase II, Single-arm Study
- Sponsor: Sun Yat-sen University
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT06547203: https://clinicaltrials.gov/study/NCT06547203

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06547203.json